Skip to main content
Erschienen in: Cardiovascular Toxicology 3/2019

30.10.2018

Methoxetamine Induces Cytotoxicity in H9c2 Cells: Possible Role of p21 Protein (Cdc42/Rac)-Activated Kinase 1

verfasst von: Kyung Sik Yoon, Sun Mi Gu, Santosh Lamichhane, Kyoung Moon Han, Jisoon Shin, Young-Hoon Kim, Soo Kyung Suh, Hye Jin Cha, Jaesuk Yun

Erschienen in: Cardiovascular Toxicology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

The abuse of new psychoactive substances (NPS) is an emerging social problem. Methoxetamine, one of the NPS, was designed as an alternative to ketamine and it was considered an NPS candidate owing to its high addictive potential. However, cardiotoxicity of the phencyclidine analogue, methoxetamine, has not been extensively evaluated. P21 protein (Cdc42/Rac)-activated kinase 1 (PAK-1) is associated with the drug-induced cardiotoxicity and hypertrophy of cardiomyocytes. In the present study, we investigated the effects of methoxetamine on rat cardiomyocytes and PAK-1. Methoxetamine (at 10 µM) reduced cell viability and PAK-1 mRNA levels in H9c2 cells. Methoxetamine treatment (100 µM) decreased the beating rate of primary cardiomyocytes. However, 100 µM methoxetamine-induced heart rate decline was less than 100 µM PCP- or ketamine-induced heart rate decline. Meanwhile, fingolimod hydrochloride (FTY720, 1 µM), a PAK-1 activator, increased cell viability and inhibited hypertrophy induced by methoxetamine in H9c2 cells. These results suggest that methoxetamine may have harmful effects on the cardiovascular system through the regulation of the expression and function of PAK-1.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Adamowicz, P., Gieron, J., Gil, D., Lechowicz, W., Skulska, A., & Tokarczyk, B. (2016). The prevalence of new psychoactive substances in biological material—a three-year review of casework in Poland. Drug Testing and Analysis, 8, 63–70.CrossRefPubMed Adamowicz, P., Gieron, J., Gil, D., Lechowicz, W., Skulska, A., & Tokarczyk, B. (2016). The prevalence of new psychoactive substances in biological material—a three-year review of casework in Poland. Drug Testing and Analysis, 8, 63–70.CrossRefPubMed
2.
Zurück zum Zitat Mounteney, J., Griffiths, P., Sedefov, R., Noor, A., Vicente, J., & Simon, R. (2016). The drug situation in Europe: An overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015. Addiction, 111, 34–48.CrossRefPubMed Mounteney, J., Griffiths, P., Sedefov, R., Noor, A., Vicente, J., & Simon, R. (2016). The drug situation in Europe: An overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015. Addiction, 111, 34–48.CrossRefPubMed
3.
Zurück zum Zitat ACMD, U.A.C.o.t.M.o.D. (2011). Consideration of the novel psychoactive substances ‘legal highs’. ACMD, U.A.C.o.t.M.o.D. (2011). Consideration of the novel psychoactive substances ‘legal highs’.
4.
Zurück zum Zitat ACMD, U.A.C.o.t.M.o.D. (2012). Advisory Council on the Misuse of Drugs, “Statement of Evidence on Methoxetamine”. ACMD, U.A.C.o.t.M.o.D. (2012). Advisory Council on the Misuse of Drugs, “Statement of Evidence on Methoxetamine”.
5.
Zurück zum Zitat Wood, D. M., Davies, S., Puchnarewicz, M., Johnston, A., & Dargan, P. I. (2012). Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. European Journal of Clinical Pharmacology, 68, 853–856.CrossRefPubMed Wood, D. M., Davies, S., Puchnarewicz, M., Johnston, A., & Dargan, P. I. (2012). Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. European Journal of Clinical Pharmacology, 68, 853–856.CrossRefPubMed
6.
Zurück zum Zitat EMCDDA, E. C..f.D.a.D.A. (2014). Report on the Risk Assessment of 2-(3-methoxyphenyl)-2-(ethylamino) Cyclohexanone (methoxetamine) in the Framework of the Council Decision on New Psychoactive Substances. EMCDDA, E. C..f.D.a.D.A. (2014). Report on the Risk Assessment of 2-(3-methoxyphenyl)-2-(ethylamino) Cyclohexanone (methoxetamine) in the Framework of the Council Decision on New Psychoactive Substances.
7.
Zurück zum Zitat Zawilska, J. B. (2014). Methoxetamine-a novel recreational drug with potent hallucinogenic properties. Toxicology Letters, 230, 402–407.CrossRefPubMed Zawilska, J. B. (2014). Methoxetamine-a novel recreational drug with potent hallucinogenic properties. Toxicology Letters, 230, 402–407.CrossRefPubMed
8.
Zurück zum Zitat Botanas, C. J., de la Pena, J. B., Dela Pena, I. J., Tampus, R., Yoon, R., Kim, H. J., Lee, Y. S., Jang, C. G., & Cheong, J. H. (2015). Methoxetamine, a ketamine derivative, produced conditioned place preference and was self-administered by rats: Evidence of its abuse potential. Pharmacology, Biochemistry, and Behavior, 133, 31–36.CrossRefPubMed Botanas, C. J., de la Pena, J. B., Dela Pena, I. J., Tampus, R., Yoon, R., Kim, H. J., Lee, Y. S., Jang, C. G., & Cheong, J. H. (2015). Methoxetamine, a ketamine derivative, produced conditioned place preference and was self-administered by rats: Evidence of its abuse potential. Pharmacology, Biochemistry, and Behavior, 133, 31–36.CrossRefPubMed
9.
Zurück zum Zitat Koren, M. J., Devereux, R. B., Casale, P. N., Savage, D. D., & Laragh, J. H. (1991). Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Annals of Internal Medicine, 114, 345–352.CrossRefPubMed Koren, M. J., Devereux, R. B., Casale, P. N., Savage, D. D., & Laragh, J. H. (1991). Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Annals of Internal Medicine, 114, 345–352.CrossRefPubMed
10.
Zurück zum Zitat Levy, D., Kenchaiah, S., Larson, M. G., Benjamin, E. J., Kupka, M. J., Ho, K. K., Murabito, J. M., & Vasan, R. S. (2002). Long-term trends in the incidence of and survival with heart failure. The New England Journal of Medicine, 347, 1397–1402.CrossRefPubMed Levy, D., Kenchaiah, S., Larson, M. G., Benjamin, E. J., Kupka, M. J., Ho, K. K., Murabito, J. M., & Vasan, R. S. (2002). Long-term trends in the incidence of and survival with heart failure. The New England Journal of Medicine, 347, 1397–1402.CrossRefPubMed
11.
Zurück zum Zitat Frey, N., Katus, H. A., Olson, E. N., & Hill, J. A. (2004). Hypertrophy of the heart: A new therapeutic target? Circulation, 109, 1580–1589.CrossRefPubMed Frey, N., Katus, H. A., Olson, E. N., & Hill, J. A. (2004). Hypertrophy of the heart: A new therapeutic target? Circulation, 109, 1580–1589.CrossRefPubMed
12.
Zurück zum Zitat Tsui, H., Zi, M., Wang, S., Chowdhury, S. K., Prehar, S., Liang, Q., Cartwright, E. J., Lei, M., Liu, W., & Wang, X. (2015). Smad3 Couples Pak1 with the antihypertrophic pathway through the E3 Ubiquitin Ligase, Fbxo32. Hypertension, 66, 1176–1183.CrossRefPubMed Tsui, H., Zi, M., Wang, S., Chowdhury, S. K., Prehar, S., Liang, Q., Cartwright, E. J., Lei, M., Liu, W., & Wang, X. (2015). Smad3 Couples Pak1 with the antihypertrophic pathway through the E3 Ubiquitin Ligase, Fbxo32. Hypertension, 66, 1176–1183.CrossRefPubMed
13.
Zurück zum Zitat Manser, E., & Lim, L. (1999). Roles of PAK family kinases. Progress in Molecular and Subcellular Biology, 22, 115–133.CrossRefPubMed Manser, E., & Lim, L. (1999). Roles of PAK family kinases. Progress in Molecular and Subcellular Biology, 22, 115–133.CrossRefPubMed
14.
Zurück zum Zitat Sussman, M. A., Welch, S., Walker, A., Klevitsky, R., Hewett, T. E., Price, R. L., Schaefer, E., & Yager, K. (2000). Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. The Journal of Clinical Investigation, 105, 875–886.CrossRefPubMedPubMedCentral Sussman, M. A., Welch, S., Walker, A., Klevitsky, R., Hewett, T. E., Price, R. L., Schaefer, E., & Yager, K. (2000). Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. The Journal of Clinical Investigation, 105, 875–886.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Ke, Y., Wang, L., Pyle, W. G., de Tombe, P. P., & Solaro, R. J. (2004). Intracellular localization and functional effects of P21-activated kinase-1 (Pak1) in cardiac myocytes. Circulation Research, 94, 194–200.CrossRefPubMed Ke, Y., Wang, L., Pyle, W. G., de Tombe, P. P., & Solaro, R. J. (2004). Intracellular localization and functional effects of P21-activated kinase-1 (Pak1) in cardiac myocytes. Circulation Research, 94, 194–200.CrossRefPubMed
16.
Zurück zum Zitat Taglieri, D. M., Monasky, M. M., Knezevic, I., Sheehan, K. A., Lei, M., Wang, X., Chernoff, J., Wolska, B. M., Ke, Y., & Solaro, R. J. (2011). Ablation of p21-activated kinase-1 in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2A. Journal of Molecular and Cellular Cardiology, 51, 988–996.CrossRefPubMedPubMedCentral Taglieri, D. M., Monasky, M. M., Knezevic, I., Sheehan, K. A., Lei, M., Wang, X., Chernoff, J., Wolska, B. M., Ke, Y., & Solaro, R. J. (2011). Ablation of p21-activated kinase-1 in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2A. Journal of Molecular and Cellular Cardiology, 51, 988–996.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Yun, J., Yoon, K. S., Lee, T. H., Lee, H., Gu, S. M., Song, Y. J., & Park, H. K. (2016). Synthetic cannabinoid, JWH-030, induces QT prolongation through hERG channel inhibition. Toxicology Research, 5(6), 1663–1671.CrossRef Yun, J., Yoon, K. S., Lee, T. H., Lee, H., Gu, S. M., Song, Y. J., & Park, H. K. (2016). Synthetic cannabinoid, JWH-030, induces QT prolongation through hERG channel inhibition. Toxicology Research, 5(6), 1663–1671.CrossRef
18.
Zurück zum Zitat Varkevisser, R., Wijers, S. C., van der Heyden, M. A., Beekman, J. D., Meine, M., & Vos, M. A. (2012). Beat-to-beat variability of repolarization as a new biomarker for proarrhythmia in vivo. Heart Rhythm: The Official Journal of the Heart Rhythm Society, 9, 1718–1726.CrossRef Varkevisser, R., Wijers, S. C., van der Heyden, M. A., Beekman, J. D., Meine, M., & Vos, M. A. (2012). Beat-to-beat variability of repolarization as a new biomarker for proarrhythmia in vivo. Heart Rhythm: The Official Journal of the Heart Rhythm Society, 9, 1718–1726.CrossRef
19.
Zurück zum Zitat Yun, J., Nagai, T., Furukawa-Hibi, Y., Kuroda, K., Kaibuchi, K., Greenberg, M. E., & Yamada, K. (2013). Neuronal Per Arnt Sim (PAS) domain protein 4 (NPAS4) regulates neurite outgrowth and phosphorylation of synapsin I. Journal of Biological Chemistry, 288, 2655–2664.CrossRefPubMed Yun, J., Nagai, T., Furukawa-Hibi, Y., Kuroda, K., Kaibuchi, K., Greenberg, M. E., & Yamada, K. (2013). Neuronal Per Arnt Sim (PAS) domain protein 4 (NPAS4) regulates neurite outgrowth and phosphorylation of synapsin I. Journal of Biological Chemistry, 288, 2655–2664.CrossRefPubMed
20.
Zurück zum Zitat Park, M. J., Lee, K. R., Shin, D. S., Chun, H. S., Kim, C. H., Ahn, S. H., & Bae, M. A. (2013). Predicted drug-induced bradycardia related cardio toxicity using a zebrafish in vivo model is highly correlated with results from in vitro tests. Toxicology Letters, 216, 9–15.CrossRefPubMed Park, M. J., Lee, K. R., Shin, D. S., Chun, H. S., Kim, C. H., Ahn, S. H., & Bae, M. A. (2013). Predicted drug-induced bradycardia related cardio toxicity using a zebrafish in vivo model is highly correlated with results from in vitro tests. Toxicology Letters, 216, 9–15.CrossRefPubMed
21.
Zurück zum Zitat Jeong, K., Kwon, H., Min, C., & Pak, Y. (2009). Modulation of the caveolin-3 localization to caveolae and STAT3 to mitochondria by catecholamine-induced cardiac hypertrophy in H9c2 cardiomyoblasts. Experimental & Molecular Medicine, 41, 226–235.CrossRef Jeong, K., Kwon, H., Min, C., & Pak, Y. (2009). Modulation of the caveolin-3 localization to caveolae and STAT3 to mitochondria by catecholamine-induced cardiac hypertrophy in H9c2 cardiomyoblasts. Experimental & Molecular Medicine, 41, 226–235.CrossRef
22.
Zurück zum Zitat Ross, E. A., Watson, M., & Goldberger, B. (2011). “Bath salts” intoxication. The New England Journal of Medicine, 365, 967–968.CrossRefPubMed Ross, E. A., Watson, M., & Goldberger, B. (2011). “Bath salts” intoxication. The New England Journal of Medicine, 365, 967–968.CrossRefPubMed
23.
Zurück zum Zitat Murphy, C. M., Dulaney, A. R., Beuhler, M. C., & Kacinko, S. (2013). “Bath salts” and “plant food” products: The experience of one regional US poison center. Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology, 9, 42–48.CrossRef Murphy, C. M., Dulaney, A. R., Beuhler, M. C., & Kacinko, S. (2013). “Bath salts” and “plant food” products: The experience of one regional US poison center. Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology, 9, 42–48.CrossRef
24.
Zurück zum Zitat Roth, B. L., Gibbons, S., Arunotayanun, W., Huang, X. P., Setola, V., Treble, R., & Iversen, L. (2018). Correction: The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS ONE, 13, e0194984.CrossRefPubMedPubMedCentral Roth, B. L., Gibbons, S., Arunotayanun, W., Huang, X. P., Setola, V., Treble, R., & Iversen, L. (2018). Correction: The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS ONE, 13, e0194984.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Dawson, P., & Moffatt, J. D. (2012). Cardiovascular toxicity of novel psychoactive drugs: Lessons from the past. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 39, 244–252.CrossRef Dawson, P., & Moffatt, J. D. (2012). Cardiovascular toxicity of novel psychoactive drugs: Lessons from the past. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 39, 244–252.CrossRef
26.
Zurück zum Zitat Corazza, O., Schifano, F., Simonato, P., Fergus, S., Assi, S., Stair, J., Corkery, J., Trincas, G., Deluca, P., Davey, Z., Blaszko, U., Demetrovics, Z., Moskalewicz, J., Enea, A., di Melchiorre, G., Mervo, B., di Furia, L., Farre, M., Flesland, L., Pasinetti, M., Pezzolesi, C., Pisarska, A., Shapiro, H., Siemann, H., Skutle, A., Enea, A., di Melchiorre, G., Sferrazza, E., Torrens, M., van der Kreeft, P., Zummo, D., & Scherbaum, N. (2012). Phenomenon of new drugs on the internet: The case of ketamine derivative methoxetamine. Human Psychopharmacology, 27, 145–149.CrossRefPubMed Corazza, O., Schifano, F., Simonato, P., Fergus, S., Assi, S., Stair, J., Corkery, J., Trincas, G., Deluca, P., Davey, Z., Blaszko, U., Demetrovics, Z., Moskalewicz, J., Enea, A., di Melchiorre, G., Mervo, B., di Furia, L., Farre, M., Flesland, L., Pasinetti, M., Pezzolesi, C., Pisarska, A., Shapiro, H., Siemann, H., Skutle, A., Enea, A., di Melchiorre, G., Sferrazza, E., Torrens, M., van der Kreeft, P., Zummo, D., & Scherbaum, N. (2012). Phenomenon of new drugs on the internet: The case of ketamine derivative methoxetamine. Human Psychopharmacology, 27, 145–149.CrossRefPubMed
27.
Zurück zum Zitat Meyer, M. R., Bach, M., Welter, J., Bovens, M., Turcant, A., & Maurer, H. H. (2013). Ketamine-derived designer drug methoxetamine: Metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn. Analytical and bioanalytical chemistry, 405, 6307–6321.CrossRefPubMed Meyer, M. R., Bach, M., Welter, J., Bovens, M., Turcant, A., & Maurer, H. H. (2013). Ketamine-derived designer drug methoxetamine: Metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn. Analytical and bioanalytical chemistry, 405, 6307–6321.CrossRefPubMed
28.
Zurück zum Zitat Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6, 614–632.CrossRefPubMed Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6, 614–632.CrossRefPubMed
29.
Zurück zum Zitat Johnstone, M. (1976). The cardiovascular effects of ketamine in man. Anaesthesia, 31, 873–882.CrossRefPubMed Johnstone, M. (1976). The cardiovascular effects of ketamine in man. Anaesthesia, 31, 873–882.CrossRefPubMed
30.
Zurück zum Zitat Reich, D. L., & Silvay, G. (1989). Ketamine: An update on the first twenty-five years of clinical experience. Canadian Journal of Anaesthesia, 36, 186–197.CrossRefPubMed Reich, D. L., & Silvay, G. (1989). Ketamine: An update on the first twenty-five years of clinical experience. Canadian Journal of Anaesthesia, 36, 186–197.CrossRefPubMed
31.
Zurück zum Zitat Hydzik, P., Gomółka, E., Sulka, A., & Cudzich-Czop, S. (2012). Acute methoxetamine poisoning–case report. Problems of Forensic Sciences, 91, 235–242. Hydzik, P., Gomółka, E., Sulka, A., & Cudzich-Czop, S. (2012). Acute methoxetamine poisoning–case report. Problems of Forensic Sciences, 91, 235–242.
33.
Zurück zum Zitat Roth, B. L., Gibbons, S., Arunotayanun, W., Huang, X. P., Setola, V., Treble, R., & Iversen, L. (2013). The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS ONE, 8, e59334.CrossRefPubMedPubMedCentral Roth, B. L., Gibbons, S., Arunotayanun, W., Huang, X. P., Setola, V., Treble, R., & Iversen, L. (2013). The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS ONE, 8, e59334.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Makhro, A., Tian, Q., Kaestner, L., Kosenkov, D., Faggian, G., Gassmann, M., Schwarzwald, C., & Bogdanova, A. (2016). Cardiac N-methyl d-aspartate receptors as a pharmacological target. Journal of Cardiovascular Pharmacology, 68, 356–373.CrossRefPubMed Makhro, A., Tian, Q., Kaestner, L., Kosenkov, D., Faggian, G., Gassmann, M., Schwarzwald, C., & Bogdanova, A. (2016). Cardiac N-methyl d-aspartate receptors as a pharmacological target. Journal of Cardiovascular Pharmacology, 68, 356–373.CrossRefPubMed
35.
Zurück zum Zitat Xie, F., Yi, S. L., Hao, L., Zhang, Y., & Zhong, J. Q. (2015). Role of group I metabotropic glutamate receptors, mGluR1/mGluR5, in connexin43 phosphorylation and inhibition of gap junctional intercellular communication in H9c2 cardiomyoblast cells. Molecular and Cellular Biochemistry, 400, 213–222.CrossRefPubMed Xie, F., Yi, S. L., Hao, L., Zhang, Y., & Zhong, J. Q. (2015). Role of group I metabotropic glutamate receptors, mGluR1/mGluR5, in connexin43 phosphorylation and inhibition of gap junctional intercellular communication in H9c2 cardiomyoblast cells. Molecular and Cellular Biochemistry, 400, 213–222.CrossRefPubMed
36.
Zurück zum Zitat Smith, S. D., Jaffer, Z. M., Chernoff, J., & Ridley, A. J. (2008). PAK1-mediated activation of ERK1/2 regulates lamellipodial dynamics. Journal of Cell Science, 121, 3729–3736.CrossRefPubMedPubMedCentral Smith, S. D., Jaffer, Z. M., Chernoff, J., & Ridley, A. J. (2008). PAK1-mediated activation of ERK1/2 regulates lamellipodial dynamics. Journal of Cell Science, 121, 3729–3736.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Wang, Y., Tsui, H., Ke, Y., Shi, Y., Li, Y., Davies, L., Cartwright, E. J., Venetucci, L., Zhang, H., Terrar, D. A., Huang, C. L., Solaro, R. J., Wang, X., & Lei, M. (2014). Pak1 is required to maintain ventricular Ca2+ homeostasis and electrophysiological stability through SERCA2a regulation in mice. Circulation: Arrhythmia and Electrophysiology, 7, 938–948. Wang, Y., Tsui, H., Ke, Y., Shi, Y., Li, Y., Davies, L., Cartwright, E. J., Venetucci, L., Zhang, H., Terrar, D. A., Huang, C. L., Solaro, R. J., Wang, X., & Lei, M. (2014). Pak1 is required to maintain ventricular Ca2+ homeostasis and electrophysiological stability through SERCA2a regulation in mice. Circulation: Arrhythmia and Electrophysiology, 7, 938–948.
38.
Zurück zum Zitat Zhang, P., Xing, J., Luo, A., Feng, J., Liu, Z., Gao, C., & Ma, J. (2013). Blockade of the human ether-a-go-go-related gene potassium channel by ketamine. Journal of Pharmacy and Pharmacology, 65, 1321–1328.CrossRefPubMed Zhang, P., Xing, J., Luo, A., Feng, J., Liu, Z., Gao, C., & Ma, J. (2013). Blockade of the human ether-a-go-go-related gene potassium channel by ketamine. Journal of Pharmacy and Pharmacology, 65, 1321–1328.CrossRefPubMed
40.
Zurück zum Zitat Kang, Y. J. (2006). Cardiac hypertrophy: A risk factor for QT-prolongation and cardiac sudden death. Toxicologic Pathology, 34, 58–66.CrossRefPubMed Kang, Y. J. (2006). Cardiac hypertrophy: A risk factor for QT-prolongation and cardiac sudden death. Toxicologic Pathology, 34, 58–66.CrossRefPubMed
Metadaten
Titel
Methoxetamine Induces Cytotoxicity in H9c2 Cells: Possible Role of p21 Protein (Cdc42/Rac)-Activated Kinase 1
verfasst von
Kyung Sik Yoon
Sun Mi Gu
Santosh Lamichhane
Kyoung Moon Han
Jisoon Shin
Young-Hoon Kim
Soo Kyung Suh
Hye Jin Cha
Jaesuk Yun
Publikationsdatum
30.10.2018
Verlag
Springer US
Erschienen in
Cardiovascular Toxicology / Ausgabe 3/2019
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI
https://doi.org/10.1007/s12012-018-9489-4

Weitere Artikel der Ausgabe 3/2019

Cardiovascular Toxicology 3/2019 Zur Ausgabe